Cargando…

Identification and Validation of Novel Immunogenic Cell Death- and DNA Damage Response-Related Molecular Patterns Correlated with Immune Status and Prognosis in Hepatocellular Carcinoma

Immunogenic cell death (ICD) and DNA damage response (DDR) are involved in cancer progression and prognosis. Currently, chemotherapy is the first-line treatment for intermediate or advanced hepatocellular carcinoma (HCC), which is mostly based on platinum and anthracyclines that induce DNA damage an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xiaokai, Wen, Jie, Zhang, Guixiong, Fan, Wenzhe, Tan, Jizhou, Liu, Haikuan, Li, Jiaping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731848/ https://www.ncbi.nlm.nih.gov/pubmed/36481605 http://dx.doi.org/10.1016/j.tranon.2022.101600

Ejemplares similares

Non-Apoptotic Programmed Cell Death-Related Gene Signature Correlates With Stemness and Immune Status and Predicts the Responsiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma
por: Zhang, Guixiong, et al.
Publicado: (2022)

Dissecting a hypoxia-related angiogenic gene signature for predicting prognosis and immune status in hepatocellular carcinoma
por: Zhang, Guixiong, et al.
Publicado: (2022)

Anti-PD-L1 antibody enhances curative effect of cryoablation via antibody-dependent cell-mediated cytotoxicity mediating PD-L1(high)CD11b(+) cells elimination in hepatocellular carcinoma
por: Tan, Jizhou, et al.
Publicado: (2023)

Clinical Significance of Peripheral Blood Lymphocyte Subtypes and Cytokines in Patients with Hepatocellular Carcinoma Treated with TACE
por: Wang, Hongyu, et al.
Publicado: (2022)

OIT3 serves as a novel biomarker of hepatocellular carcinoma by mediating ferroptosis via regulating the arachidonic acid metabolism
por: Wen, Jie, et al.
Publicado: (2022)

Corrigendum: OIT3 serves as a novel biomarker of hepatocellular carcinoma by mediating ferroptosis via regulating the arachidonic acid metabolism
por: Wen, Jie, et al.
Publicado: (2022)

High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39(+)CD8(+) T cells
por: Liu, Ting, et al.
Publicado: (2021)

Dynamic Changes in the Neutrophil-to-Lymphocyte Ratio Predict the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
por: Wang, Hongyu, et al.
Publicado: (2020)

Development and Validation of a Novel Prognosis Model Based on a Panel of Three Immunogenic Cell Death-Related Genes for Non-Cirrhotic Hepatocellular Carcinoma
por: Gong, Jiaojiao, et al.
Publicado: (2023)

Prognostic Value of TP53 Mutation for Transcatheter Arterial Chemoembolization Failure/Refractoriness in HBV-Related Advanced Hepatocellular Carcinoma
por: Xue, Miao, et al.
Publicado: (2020)

Exploration and validation of a combined immune and metabolism gene signature for prognosis prediction of colorectal cancer
por: Xiao, Yitai, et al.
Publicado: (2022)

Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma
por: Hu, Yuanyuan, et al.
Publicado: (2022)

Comprehensive analysis of immunogenic cell death associated genes expression, tumor microenvironment, and prognosis in hepatocellular carcinoma
por: Xiang, Jiankang, et al.
Publicado: (2023)

Immunogenic cell death-related classifications guide prognosis and immunotherapy in osteosarcoma
por: Zong, Yuan, et al.
Publicado: (2023)

Identification and validation of immunogenic cell death-related score in uveal melanoma to improve prediction of prognosis and response to immunotherapy
por: Li, Xiaoyan, et al.
Publicado: (2023)

Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma
por: Liu, Chao-Qun, et al.
Publicado: (2018)

DNA damage predicts prognosis and treatment response in colorectal liver metastases superior to immunogenic cell death and T cells
por: Laengle, Johannes, et al.
Publicado: (2018)

A novel immunogenic cell death signature for the prediction of prognosis and therapies in glioma
por: Zhang, Jianhua, et al.
Publicado: (2023)

Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study
por: Zhang, Yingqiang, et al.
Publicado: (2019)

DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma
por: Chen, Yunfei, et al.
Publicado: (2021)

An immunogenic cell death-associated classification predictions are important for breast invasive carcinoma prognosis and immunotherapy
por: Liao, Xinghe, et al.
Publicado: (2022)

Construction of an immunogenic cell death-based risk score prognosis model in breast cancer
por: Li, Yanling, et al.
Publicado: (2022)

Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression
por: Zou, Xinhua, et al.
Publicado: (2021)

Intrinsic Immunogenic Tumor Cell Death Subtypes Delineate Prognosis and Responsiveness to Immunotherapy in Lung Adenocarcinoma
por: He, Xiaotian, et al.
Publicado: (2023)

Prognostic value and immune landscapes of immunogenic cell death-related lncRNAs in hepatocellular carcinoma
por: Chen, Wanying, et al.
Publicado: (2023)

Molecular characterization of immunogenic cell death indicates prognosis and tumor microenvironment infiltration in osteosarcoma
por: Liu, Zhongyue, et al.
Publicado: (2022)

Prolonged progression‐free survival achieved by octreotide LAR plus transarterial embolization in low‐to‐intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden
por: Liu, Yiming, et al.
Publicado: (2022)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Survival and Metastasis for Recurrent Hepatocellular Carcinoma after Transarterial Chemoembolization
por: Fan, Wenzhe, et al.
Publicado: (2015)

The Impact of Socioeconomic Status on Staging, Prognosis in Hepatocellular Carcinoma
por: Zhou, Yongjie, et al.
Publicado: (2022)

Comprehensive characterisation of immunogenic cell death in melanoma revealing the association with prognosis and tumor immune microenvironment
por: Ren, Jie, et al.
Publicado: (2022)

Unresectable Hepatocellular Carcinoma: Transcatheter Arterial Chemoembolization Combined With Microwave Ablation vs. Combined With Cryoablation
por: Wei, Jialiang, et al.
Publicado: (2020)

Identification and Validation of Necroptosis-Related LncRNA Signature in Hepatocellular Carcinoma for Prognosis Estimation and Microenvironment Status
por: Chen, Cong, et al.
Publicado: (2022)

Damage-Associated Molecular Patterns Modulation by microRNA: Relevance on Immunogenic Cell Death and Cancer Treatment Outcome
por: Lamberti, María Julia, et al.
Publicado: (2021)

DNA damage repair-related gene signature for identifying the immune status and predicting the prognosis of hepatocellular carcinoma
por: Lu, Yongpan, et al.
Publicado: (2023)

Immunogenic cell death-associated biomarkers classification predicts prognosis and immunotherapy efficacy in pancreatic ductal adenocarcinoma
por: Peng, Wenguang, et al.
Publicado: (2023)

Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma
por: Chen, Lizhu, et al.
Publicado: (2023)

Targeted inhibition of STAT3 induces immunogenic cell death of hepatocellular carcinoma cells via glycolysis
por: Li, Ya, et al.
Publicado: (2022)

Mecheliolide elicits ROS-mediated ERS driven immunogenic cell death in hepatocellular carcinoma
por: Xu, Zhongren, et al.
Publicado: (2022)

The analysis of immunogenic cell death induced by ablation at different temperatures in hepatocellular carcinoma cells
por: Wang, Mengdong, et al.
Publicado: (2023)

Construction and validation of a model based on immunogenic cell death-associated lncRNAs to predict prognosis and direct therapy for kidney renal clear cell carcinoma
por: Cai, Chenxi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aata4h5j29sjoocsh7vpu4898a